Topical and oral bexarotene
Article first published online: 4 OCT 2013
© 2013 Wiley Periodicals, Inc.
Special Issue: Effects and Side Effects of Topical and Systemic Retinoids
Volume 26, Issue 5, pages 400–403, September/October 2013
How to Cite
Schadt, C. R. (2013), Topical and oral bexarotene. Dermatologic Therapy, 26: 400–403. doi: 10.1111/dth.12087
- Issue published online: 4 OCT 2013
- Article first published online: 4 OCT 2013
- cutaneous T cell lymphoma;
Bexarotene is a retinoid that specifically binds retinoid X receptors and has numerous effects on cellular growth and differentiation. It is approved for the treatment of cutaneous T cell lymphoma both topically and systemically. Adverse effects include hyperlipidemia, central hypothyroidism, and neutropenia with bexarotene capsules, and an irritant dermatitis with bexarotene gel. With aggressive management of these potential side effects, bexarotene is an additional option in the armamentarium for management of cutaneous T cell lymphoma.